Antithrombotic Drug with Low Risk of Bleeding
Exhibitor: CENTER FOR BIOMEDICAL RESEARCH AND DEVELOPMENT
Booth No: N416
Characteristic
The current fibrinolytic therapy or percutaneous coronary intervention (PCI) needs to be combined with anti-platelet drugs for subsequent restenosis or recurrent thrombosis. Antithrombotic drugs in the market are associated with significant bleeding risk and thrombocytopenia. We now have successfully developed a novel antithrombotic drug without these side effects.
Other Products
-
Fibrin and Platelet-targeting Thrombolytic Drug
-
Bispecific Drugs for Cancers
-
Anti-fibrotic Drug Targeting ECM
-
Modification Platforms for Protein Therapeutics
-
Protein Production and GLP Laboratory
Highest Rated Products
-
WINMAPᵀᴹ
-
DS MAPs
-
WINMAP™ Mini
-
Power Patch
-
V Patch
-
Vaccine Microarray Patches
-
Pneumatic Liquid Filling Machine
-
Powder Machine-High Speed Mixer / Granulator
-
Planetary Vacuum Mixer
-
SEMI-AUTOMATIC EYESHADOW PRESS MACHINE
-
2ton Mixing and Melting Tank with Storage Tanks
-
High Speed Mixing Machine
-
In-Line Homogenizer
-
VACUUM EMULSIFY MIXING EQUIPMENT (Bottom Homogenized Series)
-
VACUUM EMULSIFY MIXING EQUIPMENT
-
VACUUM EMULSIFY MIXING EQUIPMENT
-
UV-Visible Spectrophotometer
-
Cell Function Assay Kit(Apoptosis/Cycle/Proliferation/Cytotoxicity/Viability)
-
Biostatistical Analysis
-
Data Management
-
CM30 Incubation Monitoring System
-
CURIOSIS Celloger Nano
-
CDMO services
-
DISCOVERY Comfort Pipettor
-
LTS Style Pipette Tips
-
Rotary Evaporator
-
Centrifugal Evaporator (Teflon coated)
-
Clinical Small Centrifuges
-
High Performance Liquid Chromatography, HPLC
-
Risk Assessment
